Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Myelomeningocoele~* Documented diagnosis of NDO, confirmed by urodynamics~* DSD (detrusor sphincter dyssynergia)~* Practicing clean intermittent catheterization (CIC)~Exclusion Criteria:~* Know genitourinary condition (other than NDO) that may cause incontinence~* Bladder augmentation surgery~* Current faecal impaction~* Electro-stimulation therapy within 2 weeks prior to visit~* Subjects with the following gastro-intestinal problems: partial or complete obstructions, decreased motility like paralytic ileus, subjects at risk of gastric retention~* Reflux grade 3 to 5~* Current urinary tract infection

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- Solifenacin succinate (Type: EXPERIMENTAL): Children aged 6 months to less than 5 years were treated with sequential titrated doses of solifenacin up to 12 weeks in the Titration period after which a fixed dose of solifenacin was given for at least 40 weeks in the Fixed-dose assessment period. Children received solifenacin once daily during these 2 periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).